Research is being conducted on new radiopharmaceuticals for ovarian cancer, exploring alternatives to traditional methods. Advances in nuclear medicine are being reviewed, with a focus on emerging strategies and technologies such as fibroblast activation protein inhibitor positron emission tomography. Clinical trials are also underway, investigating the potential of various radiopharmaceutical therapies for the disease.